Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
US-2018200338-A1 · Jul 19, 2018 · US
Mutant interleukin-2 polypeptides
US11111312B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11111312-B2 |
| Application number | US-201816198531-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2018 |
| Priority date | Feb 10, 2011 |
| Publication date | Sep 7, 2021 |
| Grant date | Sep 7, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated polynucleotide encoding a polypeptide of an immunoconjugate, wherein the immunoconjugate comprises a mutant interleukin-2 (IL-2) polypeptide and an immunoglobulin molecule that specifically binds Fibroblast Activation Protein (FAP), and the isolated polynucleotide comprising the sequence of SEQ ID NO: 302. 2. An expression vector comprising the isolated polynucleotide of claim 1 . 3. An expression vector for expressing an immunoconjugate, wherein the immunoconjugate comprises a mutant interleukin-2 (IL-2) polypeptide and an immunoglobulin molecule that specifically binds Fibroblast Activation Protein (FAP), and the expression vector comprising: a) an isolated polynucleotide comprising the sequence of SEQ ID NO: 302; b) an isolated polynucleotide comprising the sequence of SEQ ID NO: 304; and c) an isolated polynucleotide comprising the sequence of SEQ ID NO: 232. 4. An isolated host cell for producing an immunoconjugate, wherein the immunoconjugate comprises a mutant interleukin-2 (IL-2) polypeptide and an immunoglobulin molecule that specifically binds Fibroblast Activation Protein (FAP), and the isolated host cell comprising: a) an isolated polynucleotide comprising the sequence of SEQ ID NO: 302; b) an isolated polynucleotide comprising the sequence of SEQ ID NO: 304; and c) an isolated polynucleotide comprising the sequence of SEQ ID NO: 232. 5. A method of producing an immunoconjugate, comprising culturing the isolated host cell of claim 4 , so that the immunoconjugate is produced, and isolating the immunoconjugate from the culture.
Assignees
Inventors
Classifications
against receptors, cell surface antigens or cell surface determinants · CPC title
- C07K14/55Primary
IL-2 · CPC title
the drug being a peptidic cytokine, e.g. an interleukin or interferon · CPC title
- A61K38/2013Primary
IL-2 · CPC title
- C07K16/40Primary
against enzymes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11111312B2 cover?
- The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells compri…
- Who is the assignee on this patent?
- Roche Glycart Ag
- What technology area does this patent fall under?
- Primary CPC classification C07K14/55. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).